Prostate cancer metastasis-suppressor genes: A current perspective

In Vivo

Volumn 12, Issue 1, 1998, Pages 49-58

  Yoshida, Barbara A ^a   Chekmareva, Marina A ^a   Wharam, James F ^a   Kadkhodaian, Mithra ^a   Stadler, Walter M ^a   Boyer, Alexandra ^a   Watabe, Kounosuke ^b   Nelson, Joel B ^c   Rinker Schaeffer, Carrie W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosome 17; Metastasis suppressor genes; Prostate cancer

Indexed keywords

HERMES ANTIGEN;

ARTICLE; CHROMOSOME 11P; CHROMOSOME 17; GENE EXPRESSION; GENE MAPPING; HUMAN; METASTASIS; NONHUMAN; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

EID: 0031955123     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Liao S: Personal communication, 1997.
2. Parker SL, Tong T, Dolden and Wingo PA: Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 1997 Mar-Apr; 47(2): 68], CA Cancer J Clin 47: 5-27, 1997.
3. Lamm DL: Cancer statistics [letter; comment], CA Cancer J Clin 40: 318-319, 1990.
4. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS and Isaacs JT: Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25: 249-265, 1994.
5. Carter HB and Coffey DS: The prostate: an increasing medical problem Prostate 16: 39-48, 1990.
6. Isaacs JT: Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer, Am J Pathol 150: 1511-1521, 1997.
7. Horm JW and Sondik EJ: Person-years of life lost due to cancer in the United States, 1970 and 1984, Am J Public Health 79: 1490-1493, 1989.
8. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusenio UB and Kraaz W: Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1: 799-803, 1989.
9. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer [see comments]. J Urol 150: 110-4, 1993.
10. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS and Epstein JI: Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy [see comments]. J Urol 152: 1077-1081, 1994.
11. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer [see comments]. J Urol 152: 1850-1857, 1994.
12. Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer, Cancer. 71: 1098-1109, 1993.
13. Gleason DF and Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
14. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD and Fidler IJ: Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150: 1571-1582, 1997.
15. Ichikawa T, Nihei N, Kuramochi H, Kawana Y, Killary AM, Rinker Schaeffer CW, Barrett JC, Isaacs JT, Kugoh H, Oshimura M and Shimazaki J: Metastasis suppressor genes for prostate cancer, Prostate Suppl 6: 31-35, 1996.
16. Rinker-Schaeffer CW, Chekmareva MA and Mohler JL: The role of motility proteins and metastasis-suppressor genes in prostate cancer progression, Stem Cells 14: 508-516, 1996.
17. Carter HB, Piantadosi S and Isaacs JT: Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143: 742-746, 1990.
18. Ichikawa T, Ichikawa Y and Isaacs JT: Genetic factors and metastatic potential of prostatic cancer. Cancer Surv 11: 35-42, 1991.
19. Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC and Isaacs JT: Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11, Cancer Res 52: 3486-3490, 1992.
20. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT and Shimazaki J: Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. Cancer Res 54: 2299-2302, 1994.
21. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugo H, Oshimura M, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT and et al: Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10. Genes Chromosomes Cancer 14: 112-119, 1995.
22. Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugoh H, Oshimura M, Hayata I, Shimazaki J and Ito H: Mapping of metastasis suppressor gene(s) for rat prostate cancer on the short arm of human chromosome 8 by irradiated microcell-mediated chromosome transfer. Genes Chromosomes Cancer 17: 260-268, 1996.
23. Rinker-Schaeffer CW, Hawkins AL, Ru N, Dong J, Stoica G, Griffin CA, Ichikawa T, Barrett JC and Isaacs JT: Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 54: 6249-6256, 1994.
24. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JK: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11pl 1.2 [see comments]. Science 268: 884-886, 1995.
25. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC and Isaacs JT: Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss, Cancer Res. 56: 4387-4390, 1996.
26. Gao AC, Lou W, Dong JT and Isaacs JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11pl3. Cancer Res 57: 846-849, 1997.
27. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H and Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cance 78: 1461-1469, 1996.
28. Bova GS and Isaacs WB: Review of allelic loss and gain in prostate cancer. World J Urol 14: 338-346, 1996.
29. Chekmareva MA, Hollowell CMP, Smith RC, Davis EM, LeBeau MM and Rinker-Schaeffer, C. W. Localization of the prostate cancer metastasis-suppressor activity on human chromosome 17, The Prostate, in press:, 1997.
30. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr LR and Brothman AR: Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer [see comments]. J Urol 155: 720-725, 1996.
31. Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT and Honn KV: Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in humanprostate cancer. Oncogene. 11: 1241-1247, 1995.
32. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C and Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181: 1333-1343, 1995.
33. Mori S, Satoh T, Koide H., Nakafuku M, Villafranca E and Kaziro Y: Inhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell- free systems. J Biol Chem 270: 28834-28838, 1995.
34. Albelda, S. M. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68: 4-17, 1993.
35. Liang P, Bauer D, Averboukh L, Warthoe P, Rohrwild M, Muller H, Strauss M and Pardee AB: Analysis of altered gene expression by differential display. Methods Enzymol 254: 304-321, 1995.
36. Chen PL, Ueng YC, Durfee T, Chen, Yang-Feng T and Lee WH: Identification of a human homologue of yeast nuc2 which interacts with the retinoblastoma protein in a specific manner. Cell Growth Differ 6: 199-210, 1995.
37. Gorlich D, Kostka S, Kraft R, Dingwall C, Laskey RA, Hartmann E and Prehn S: Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr Biol 5: 383-392, 1995.
38. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS and Cress AE: Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 119: 637-644, 1993.
39. Tugendreich S, Tomkiel J, Earnshaw W and Hieter P: CDC27Hs colocalizes with CDC16Hs to the centrosome and mitotic spindle and is essential for the metaphase to anaphase transition. Cell 81: 261-268, 1995.
40. Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL and Chang TS: The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril 63: 1101-1107, 1995.
41. Koi M, Johnson LA and Feinberg AP: A novel general strategy for cloning tumor suppressor genes using radiation-reduced chromosomal superfragments. Tohoku J Exp Med 168: 167-8, 1992.
42. Nelson DL, Ledbetter SA, Corbo L, Victoria MF, Ramirez-Solis R, Webster TD, Ledbetter DH and Caskey CT: Alu polymerase chain reaction: a method for rapid isolation of human- specific sequences from complex DNA sources. Proc Natl Acad Sci USA 86: 6686-90, 1989.
43. Anti-integrin ß3, anti-integrin ß4 anti-PECAM-1, and anti-GPIIb antibodies were purchased from Pharmingen, San Diego, CA (catalog numbers 33821A, 33691A, 30881A, and 31091A respectively). Isotype control and FITC-conjugated antibodies were also purchased from Pharmingen (catalog numbers 11031D, 03001D, 03061D, 02004D, 02064D, and 10104D).